Title: Zika Vaccines Market - Industry Insights, Size, Shares, Trends, Outlook, and Opportunity Analysis, 2018–2026
1Zika Vaccines Market - Industry Insights, Size,
Shares, Trends, Outlook, and Opportunity
Analysis, 20182026
Zika vaccines are developed for immunization
prevention against diseases caused by Zika
virus. This virus belongs to genus Flavivirus and
is transmitted by Aedes mosquitoes. The virus
can also be transmitted through blood
transfusion, sexual contact or from infected
pregnant women to the fetus. Diagnosis of this
infection is confirmed by detecting viral DNA
through PCR. However, only 1 in 4 people with
zika infection are prone to develop symptoms. In
November 2016, the World Health Organization
(WHO) declared that zika infection no longer
constitutes a Public Health Emergency of
International Concern (PHEIC) as major cases of
zika virus were asymptomatic. Request Sample
Copy of Research Reporthttps//www.coherentmarke
tinsights.com/insight/request-sample/413 Continu
ous increase in human clinical trials and rise in
number of zika cases will drive the growth of
Zika vaccines market As of March 2016, 67
companies and research institutions were working
on various kinds of RD projects and clinical
trials aided to develop effective vaccines
against zika virus. The FDA approved the first
human clinical trial for GLS5700 in June 2016,
a zika vaccine being developed by Inovio
Pharmaceuticals. Further in 2017, a grant was
approved for phase 2 clinical trials for a DNA
vaccine conducted by NIAIDs Vaccine Research
Center (VRC).
2- Increasing awareness among the population would
aid in controlling the incidence rate of zika
infection. The WHO implemented a global framework
for creating public awareness through its Zika
Strategic Response Framework and Joint Plan in
February 2016. This plan outlines all the points
to be taken care of at the time of infections.
In June 2016, WHO Regional Office for Europe
developed a training curriculum to increase
awareness by the publication of Zika Risk
Assessment for European Region. - High investment costs required for RD and the
development of effective zika virus vaccines
serves as a restraining factor for the global
zika vaccines market. - While major of the Zika virus cases occur in
tropical regions such as Brazil, Paraguay,
Venezuela, Colombia and Suriname, there are
higher chances of mosquito infections in
tropical areas of the U.S. like Texas and
Florida. According to Pan American Health
Organization, around 1,246 suspected and
confirmed cases were reported between
epidemiological week (EW) 10 and EW 14 of 2016 in
the sub region which involves Brazil, Argentina,
Peru and Ecuador. - Some key players operating in the zika vaccines
market are Cerus Corporation, Biken Inc,
GlaxoSmithKline plc, Bharat Biotech International
Pvt. Ltd, GeneOne Life Science, Inovio
Pharmaceuticals, Immunovaccine Inc., NewLink
Genetics Corp. and Sanofi S.A. - Inquire Here Before Purchasehttps//www.coherentm
arketinsights.com/insight/talk-to- analyst/413 - Zika Vaccines Market Taxonomy
- There are different types of vaccines that
provide protection against Zika virus - DNA-based vaccines
- Inactivated vaccines
- Live-attenuated vaccines
- mRNA vaccines
3and competitive analysis through various recommend
ations related to emerging market trends,
technologies, and potential absolute dollar
opportunity. Contact Us Mr. Shah Coherent
Market Insights 1001 4th Ave, 3200 Seattle, WA
98154 Tel 1-206-701-6702 Email
sales_at_coherentmarketinsights.com